Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2017)
14 slides from Genetic Technologies's shareholder meeting presentation, Nov 23, 2017
Slide 1: 2017 Annual General Meeting
For personal use only ASX ANNOUNCEMENT 23 November 2017 2017 Annual General Meeting Melbourne, Australia; 23 November 2017: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) is pleased to release the attached slide show presentation which will be delivered by its Chief Executive Offic
Slide 2: For personal use only
and awards fees. Since this information may involve risks and uncertainties and are subject to change at any For personal use only time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its perio
Slide 3: Genetic Technologies Limited Annual General Meeting
Genetic Technologies Limited For personal use only Annual General Meeting Thursday, 23 November 2017 1
Slide 4: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business ach
Slide 5: Major Achievements Since Last AGM
Major Achievements Since Last AGM For personal use only With the focus geared toward improving BREVAGenplus’s overall market awareness and adoption among healthcare providers and patients, the Company; Activated promotional campaign around the Susan G. Komen® Dallas, Texas Race for the Cure®, to coi
Slide 6: Major Achievements Since Last AGM
Major Achievements Since Last AGM (Cont.) For personal use only Maintained a strong cash position, with $11.0m in cash as at 30 June 2017 Completed an $8.1M capital raising in December 2016 Executed exclusive worldwide license Agreement with The University of Melbourne; potential to develop Colorect
Slide 7: Brand Awareness-Exclusive Spokesperson
Brand Awareness-Exclusive Spokesperson For personal use only Verizon IndyCar series driver Pippa Mann has become the exclusive spokesperson for BREVAGenplus. BREVAGenplus.com, supportive marketing collateral and social media are aligned with the Pippa Mann image and the "Know Your Risk" call to acti
Slide 8: First Quarter - FY18 Update: Colorectal cancer
First Quarter - FY18 Update For personal use only Colorectal cancer In November 2016, executed exclusive worldwide license agreement with The University of Melbourne, with the potential to develop a novel colorectal cancer risk assessment test A scientific validation study supporting this work has b
Slide 9: First Quarter - FY18 Update: Ohio State University partnership
First Quarter - FY18 Update (Cont.) For personal use only Clinical research partnership with Ohio State University The Study is investigating the impact of a polygenic risk score on the health management of already high risk BRCA1/BRCA2 carriers Ohio State University Review Board Approval for the pr
Slide 10: First Quarter - FY18 Update: Strategic review initiative
First Quarter - FY18 Update (Cont.) For personal use only Strategic review initiative Retained Roth Capital Partners to serve as a financial advisor and to manage the review campaign Working side by side with Roth Capital Partners to progress the strategic review initiative As previously announced,
Slide 11: Focus for FY 2018
Focus for FY 2018 For personal use only The repositioning and repricing of BREVAGenplus, were key initiatives during the past year Market feedback suggests that; - the self-pay program is being well received by primary care providers - that there is a growing need for a breast cancer risk assessment
Slide 12: Focus for FY 2018: Online commercial platform
Focus for FY 2018 (Cont.) For personal use only Transitioning to an online commercial platform for BREVAGenplus An online portal for Consumer Initiated Testing Physician Oversight Access to comprehensive educational background on BREVAGenplus 10
Slide 13: Focus for FY 2018: Online platform (Cont.)
Focus for FY 2018 (Cont.) For personal use only Transitioning to an online commercial platform for BREVAGenplus (Cont.) Test reports pre-approved with physician oversight Reports delivered electronically to patients Physician Oversight Pre-approval prior to report delivery 11
Slide 14: Focus for FY 2018: Strategic review initiative
Focus for FY 2018 (Cont.) For personal use only Strategic review initiative Continue to work side by side with Roth Capital Partners to progress the strategic review initiative Manage operating cost base and cash flow with the aim of maximising reinvestment in product development, while ensuring ade
Genetic Technologies — Shareholder Meeting (November 2017) on 6ix